ArticleTranslational cancer research2021
Clinical pathological analysis of newly diagnosed malignant pelvic tumors during pregnancy.
Article in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study sought to investigate the pathological and clinical characteristics of newly developed malignant pelvic tumors during pregnancy.
methodsA retrospective analysis was conducted of 20 patients with newly developed malignant pelvic tumors during pregnancy who were admitted to hospital from January 1, 2012 to March 31, 2020. The patients were grouped according to the histological tumor source, evaluated using a chi-square test and Kaplan-Meier analysis, and their clinical and pathological characteristics were examined.
resultsOf the 20 patients, 14 had primary tumors and 6 had metastatic tumors. The average age of the patients in the metastatic tumor group was higher than that of patients in the primary tumor group (P=0.038). Notably, patients in both groups were at an advanced tumor stage when they were diagnosed. A significant difference between the 2 groups (P<0.001) was found in the clinical presents and the outcomes. The survival rates of the 2 groups differed significantly (P<0.001). Patients in the primary tumor group all survived without tumors. Conversely, only 1 patient in the metastatic tumor group survived without a tumor during the follow-up period, and 5 patients in this group did not survive. The metastatic rates of the examined placentas were 1/6 and 3/5 for the primary and metastatic tumor groups, respectively (P=0.545). The histological distribution of the newly developed malignant pelvic tumors during pregnancy was diverse, and different to those in the non-pregnancy period. Additionally, 6 patients had metastatic tumors, and the proportion of metastatic tumors was significantly higher than that of non-pregnancy patients (P<0.001; 3.53%
conclusionsNewly diagnosed malignant pelvic tumors during pregnancy were different from the non-pregnant in the tissue origin, pathological grade, clinical presenting, and outcomes. The metastatic tumors pose a serious threat to the lives and health of pregnant women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.